Obesity Clinical Trial
— oPTiMuMOfficial title:
Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women - Pilot Study
NCT number | NCT02537145 |
Other study ID # | P9624 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | September 2015 |
Est. completion date | December 2017 |
Verified date | September 2018 |
Source | TNO |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this pilot study is to determine the feasibility of Do-It-Yourself studies in pregnant women to detect changes in health parameters by assessing compliance and user experiences of participants. Besides, the measured health will be analysed to increase insight in physiological development in pregnant women.
Status | Terminated |
Enrollment | 16 |
Est. completion date | December 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Pregnant between 12-15 weeks at the start of the study; 2. Healthy as assessed by the Health and Lifestyle questionnaire (P9624 F02); 3. Body mass index: - BMI 18,5 - 25 for the lean group - BMI = 30 for the obese group; 4. Able to use self-monitoring devices; 5. Voluntary participation; 6. Having given written informed consent; 7. Willing to comply with study procedures; 8. Willingness to share pseudonymised data on measured health parameters with external parties that provide the measuring devices (including MijnEetmeter, Moves and NRC) for reasons of synchronisation with the study database; 9. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data by TNO; 10. Have internet access at home; 11. Subjects should own a Smartphone with Bluetooth that runs either a recent version of iOS or Android. Exclusion Criteria: 1. Use of concomitant medication; 2. Having a history of medical or surgical events that may significantly affect the study outcome, including physical limitations or cardio-vascular events; 3. Having a (history of a) medical condition that might significantly affect the study outcome as judged by the principal investigator and health and life style questionnaire. This includes diabetes type 1 or 2, gastrointestinal dysfunction, diseases related to inflammation, or a psychiatric disorder; 4. Hypertension: systolic blood pressure >160 mmHg, diastolic blood pressure >90 mmHg; 5. Having a pacemaker; 6. Previous pregnancy with medical issues (e.g. pre-eclampsia); 7. Reported slimming or medically prescribed diet; 8. Physical, mental or practical limitations in using computerized systems; 9. Alcohol consumption > 14 units (drinks)/week; 10. Smoking; 11. Reported unexplained weight loss or gain of > 2 kg in the three months prior to the pre-study screening / pregnancy; 12. Recent blood donation (<1 month prior to the start of the study); 13. Not willing to give up blood donation during the study; 14. Personnel of TNO and their partner. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Spaarne Gasthuis | Hoofddorp | Noord Holland |
Lead Sponsor | Collaborator |
---|---|
W.J. Pasman | Spaarne Gasthuis |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | compliance (percentage of complete datasets) | as a measure of the potential of DIY-monitoring in pregnant women | end of study (3 months after giving birth) | |
Primary | Capability of and burden for participants of the use of DIY tools | as assessed by a questionnaire on user-experience with do-it-yourself devices in an at-home setting | end of study (3 months after giving birth) | |
Secondary | fasting blood glucose | as measured using a do-it-yourself glucose meter after an overnight fast | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52 | |
Secondary | body weight | as measured by a smart-scale | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52 | |
Secondary | physical activity (calories burned, minutes of physical activity, number of steps) | participants continuously wear the activity tracker during the day for the whole week in each of the above mentioned measurement-weeks | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52 | |
Secondary | blood pressure (diastolic, systolic, heart rate) | as measured with a do-it-yourself blood pressure meter | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 of pregnancy; optionally after delivery in w42, 44, 46, 48, 50, 52 | |
Secondary | GPS location | measured with an app that will be installed on the Smartphone of the participant at enrollment in the study | measured continuously during the entire study | |
Secondary | Cholesterol (total cholesterol, HDL, LDL, triglycerides, cholesterol/HDL-ratio) | measured using a do-it-yourself cholesterol meter | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | oral glucose tolerance test (glucose, insulin, c-peptide) | in week 16 the test will be done in a clinical setting; the other tests will be done at home by the participants | baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | fecal and salivary microbiota composition | using do-it-yourself sample collection kits (at home by participants; samples will be send to the lab) | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally also in w18, 27 and 36, and after delivery in w44, 48 and 52 | |
Secondary | dried blood spots for HbA1c, fatty acids and blood biomarkers | do-it-yourself using finger-prick and blood spot collection cards that can be send to the lab. | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | cortisol in hair | measured by taking a hair sample that is send to the lab | at the end of the study (3 months after delivery; week 52) | |
Secondary | food intake as measured by a web-application | in each measurement week, participants will register their food intake on two week days and one weekend day | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | cognition | using online cognition tests (on a study portal) | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | Groninger Sleep Scale | online; can be accessed via the study portal | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | Vita16 - vitality questionnaire | online; can be accessed via the study portal | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 | |
Secondary | visual analogue scales for general health | online; can be accessed via the study portal | at enrollment (between w12-15 of pregnancy), baseline (w16 of pregnancy), w24, 32, 40 of pregnancy; optionally after delivery in w52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |